CBUS — Cibus, Inc.

Summary of Cibus, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash and Cash Equivalents: $9.9 million as of December 31, 2025.
• Public Offering: Raised $22.3 million in January 2026, extending financial runway.
• Net Loss: $31.9 million for Q4 2025, compared to $25.8 million in Q4 2024.
• R&D Expenses: Decreased to $9.4 million from $12.4 million year-over-year due to cost-saving initiatives.
• SG&A Expenses: Reduced to $5.1 million from $6.8 million year-over-year.
• Royalty Liability Interest Expense: Increased to $9.4 million from $8.2 million year-over-year.

2. Strategic Updates and Business Highlights

• Customer Base Expansion: Secured seven rice customers with a potential annual royalty opportunity exceeding $200 million.
• Regulatory Progress: Significant developments in gene editing regulations, particularly in the EU, which could unlock a 100 million-acre market.
• Commercialization Initiatives: Established a non-binding LOI with Interox for herbicide commercialization in Latin America, targeting markets like Ecuador and Colombia starting in 2027.
• Technological Advancements: Enhanced editing efficiency and streamlined processes through AI and automation, enabling faster trait development.

3. Forward Guidance and Outlook

• Revenue Generation: Anticipates initial market entry in Latin America in 2027, with potential U.S. expansion in 2028 and entry into India and Asia by 2030.
• Operational Focus: Plans to maintain a disciplined approach to capital allocation, targeting annual net cash usage of approximately $30 million or less in 2026.
• Regulatory Milestones: Monitoring EU parliamentary sessions for further regulatory clarity, which could catalyze commercial opportunities.

4. Bad News, Challenges, or Points of Concern

• Net Loss Increase: The net loss widened compared to the previous year, raising concerns about financial sustainability.
• Revenue Timing Issues: Some collaboration revenue and earnings came in below expectations, attributed to timing rather than operational issues.
• Market Entry Delays: While there are promising developments, significant revenue from India is not expected until 2029-2030, indicating a longer wait for returns from that market.

5. Notable Q&A Insights

• EU Regulatory Impact: Management expressed optimism about the EU's new gene editing framework, which could enhance commercialization efforts in Europe, particularly for canola and winter oilseed rape.
• Commercialization Steps in Latin America: Management outlined a clear path for commercialization in Latin America, emphasizing the importance of elite genetics and the timeline for trait registration.
• Gene Edits as a Service: There is growing interest from partners in utilizing Cibus's gene editing capabilities, with favorable negotiations expected due to the accelerated value addition for customers.
• Fragrance Market Potential: Management highlighted the potential for scaling fragrance projects, indicating interest in expanding beyond initial collaborations.

Overall, Cibus, Inc. is positioned for growth with a focus on strategic partnerships and regulatory advancements, although it faces challenges related to financial losses and market entry timelines.